Preclinical Vaccine Study of Plasmodium vivax Circumsporozoite Protein Derived-Synthetic Polypeptides Formulated in Montanide ISA 720 and Montanide ISA 51 Adjuvants
نویسندگان
چکیده
منابع مشابه
Safety data of Montanide ISA 51 VG and Montanide ISA 720 VG, two adjuvants dedicated to human therapeutic vaccines
Introduction Montanide ISA 51 VG and Montanide ISA 720 VG are two novel adjuvants dedicated to human therapeutic vaccines. They have been used in more than 200 clinical trials involving cancer, AIDS, malaria or autoimmune disease vaccines and involving an accrual of more than 20000 patients. The adjuvants are rendering stable water-in-oil emulsions when mixed with water based antigenic media. M...
متن کاملSustained release of actives with Montanide™ ISA 51 VG and Montanide™ ISA 720 VG, two adjuvants dedicated to human therapeutic vaccines
Introduction MontanideTM ISA 51 VG and MontanideTM ISA 720 VG are adjuvants dedicated to human therapeutic vaccines. The adjuvants are rendering stable water-in-oil (W/O) emulsions when mixed with water phase. In these formulations the active ingredients are entrapped in droplets of water surrounded by continuous oil phase. It allows a protection against degradation and slow release of the acti...
متن کاملSafety and Immunogenicity of a Recombinant Plasmodium falciparum AMA1 Malaria Vaccine Adjuvanted with Alhydrogel™, Montanide ISA 720 or AS02
BACKGROUND Plasmodium falciparum Apical Membrane Antigen 1 (PfAMA1) is a candidate vaccine antigen expressed by merozoites and sporozoites. It plays a key role in red blood cell and hepatocyte invasion that can be blocked by antibodies. METHODOLOGY/PRINCIPAL FINDINGS We assessed the safety and immunogenicity of recombinant PfAMA1 in a dose-escalating, phase Ia trial. PfAMA1 FVO strain, produc...
متن کاملPhase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51
BACKGROUND Pfs25 and Pvs25, surface proteins of mosquito stage of the malaria parasites P. falciparum and P. vivax, respectively, are leading candidates for vaccines preventing malaria transmission by mosquitoes. This single blinded, dose escalating, controlled Phase 1 study assessed the safety and immunogenicity of recombinant Pfs25 and Pvs25 formulated with Montanide ISA 51, a water-in-oil em...
متن کاملSafety and Immunogenicity of a Malaria Vaccine, Plasmodium falciparum AMA-1/MSP-1 Chimeric Protein Formulated in Montanide ISA 720 in Healthy Adults
BACKGROUND The P. falciparum chimeric protein 2.9 (PfCP-2.9) consisting of the sequences of MSP1-19 and AMA-1 (III) is a malaria vaccine candidate that was found to induce inhibitory antibodies in rabbits and monkeys. This was a phase I randomized, single-blind, placebo-controlled, dose-escalation study to evaluate the safety and immunogenicity of the PfCP-2.9 formulated with a novel adjuvant M...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The American Journal of Tropical Medicine and Hygiene
سال: 2011
ISSN: 0002-9637,1476-1645
DOI: 10.4269/ajtmh.2011.10-0110